AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05333237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention #3: Generic Glucose Solution
Description: Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
Study NCT05420948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A chemotherapy drug used to treat cancer.
Study NCT05420948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A chemotherapy drug used to treat cancer.
Study NCT05425017 — intervention group
Intervention type: OTHER
Intervention: Range of motion with spinal adjustment
Description: With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion
Study NCT06252376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head-up tilt table
Description: Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
Study NCT06481670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: The >50 g carbohydrate drink will be consumed up to 2 hours prior to surgery.
Study NCT05626491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Description: Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
Study NCT05626491 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Description: Patients receive sham treatment (no active stimulation) every other day via a headband.
Study NCT05285891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
Study NCT05285891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Ocrelizumab
Description: Placebo infusions every 6 months from Month 30 through Month 48.
Study NCT04770493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
Study NCT04770493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sugar pill)
Study NCT04882553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of esophageal pressure
Description: Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
Study NCT04882553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Registration of respiratory mechanics
Description: Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
Study NCT06436352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulotomy and fixation
Description: Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex.
Study NCT06436352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation only
Description: we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex.
Study NCT05124912 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation Therapy
Description: Post-op hypofractionated therapy or no radiation therapy
Study NCT05124912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Steroid Therapy
Description: Best medical management with steroid therapy
Study NCT05124912 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Interstitial Thermal Therapy
Description: Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
Study NCT04516603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR
Description: Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
Study NCT04516603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active component
Study NCT05144347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL114
Description: Tablets of XL114
Study NCT06138171 — intervention group
Intervention type: OTHER
Intervention: Psychological self-reported measures assesment (questionnaire)
Description: The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
Study NCT05624112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab solution in a pre-filled syringe for Subcutaneous injection
Study NCT06444360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
Study NCT06444360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSOC
Description: The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
Study NCT04683913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot rotation modification
Description: The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable.
Study NCT04683913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting Period - Delayed Group
Description: Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
Study NCT06350565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
Study NCT05261711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1
Description: This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
Study NCT06400615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD109
Description: Oral administration at bedtime
Study NCT05395546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCBT-I
Description: 1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation
Study NCT06331611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF monitoring
Description: Reversal with Sugammadex will be based on TOF monitoring
Study NCT06331611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF monitoring
Description: Reversal with Sugammadex will be based on TOF monitoring
Study NCT06168149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fetal lung elastography measurement
Description: Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file.
Study NCT04431297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness Rounds
Description: Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
Study NCT06051175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bitter taste perception
Description: Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study NCT06051175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salty taste perception
Description: Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study NCT06051175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet taste perception
Description: Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 0.5g bid
Study NCT05023577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd
Study NCT05054322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
Study NCT05720975 — intervention group
Intervention type: DEVICE
Intervention: iNstroke
Description: Patients to undergo thromboaspiration with iNstroke.
Study NCT04870723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth for Covid-19 prevention and support
Description: 3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
Study NCT04870723 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: eHealth for Covid-19 prevention and support
Description: 3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
Study NCT06371144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Analgestic
Study NCT06371144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Analgestic
Study NCT05260164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFEM+RF
Description: Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
Study NCT06051175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acid taste perception
Description: Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study NCT06051175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umami taste perception
Description: Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response.
Study NCT05045534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of TB-840 treatment with Placebo
Description: Single dose or Multiple Dose of TB-840 treatment
Study NCT05729919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft technique
Description: A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface
Study NCT06576466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate. Guinama brand with CE marking. Code 89823.
Study NCT06576466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrinomaltose. Guinama brand with CE marking. Code 91146.
Study NCT06293937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numerical label
Description: Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
Study NCT06293937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive text-only label
Description: Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
Study NCT06293937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
Study NCT06293937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Separated interpretive magnifying glass icon label
Description: Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
Study NCT05114746 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously at a dose of 7.4 GBq (+/- 10%). A 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
Study NCT05114746 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: 68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi).
Study NCT05114746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive/best standard of care
Description: Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
Study NCT04678401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
Study NCT04678401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg-enriched donor cell
Description: Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmodified donor T Cell
Description: Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
Study NCT04678401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD34+ Haplo Peripheral Blood Stem Cell
Description: CD34+ Haplo Peripheral Blood Stem Cell Transplantation